A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: Review of the literature and proposal on the criteria of evaluation

Histopathology

Volumn 51, Issue 4, 2007, Pages 440-451

  Van Den Eynden, G G ^a,f   Colpaert, C G ^a   Couvelard, A ^d   Pezzella, F ^e   Dirix, L Y ^a   Vermeulen, P B ^a   Van Marck, E A ^a   Hasebe, T ^b,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d BEAUJON HOSPITAL   (France)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f Oncologisch Centrum   (Belgium)

Author keywords

Angiogenesis; Fibrotic focus; Hypoxia; Lymphangiogenesis

Indexed keywords

BREAST ADENOCARCINOMA; BREAST CANCER; BREAST EXAMINATION; BREAST FIBROSIS; CANCER INVASION; CANCER PATIENT; CELL FUNCTION; CELL INTERACTION; CLINICAL FEATURE; DISEASE MARKER; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; HYPOXIA; LYMPHANGIOGENESIS; MEDICAL PARAMETERS; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; SOLID TUMOR; STROMA CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

BREAST; BREAST NEOPLASMS; CELL HYPOXIA; FEMALE; FIBROSIS; HUMANS; LYMPHANGIOGENESIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548683776     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02761.x     Document Type: Review

References (62)

1. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 1996 76 69 125.
2. Hasebe T, Tsuda H, Hirohashi S et al. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J. Cancer Res. 1996 87 385 394.
3. Hasebe T, Sasaki S, Imoto S, Ochiai A. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod. Pathol. 2001 14 325 337.
4. Hasebe T, Tsuda H, Hirohashi S et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res. Treat. 1998 49 195 208.
5. Hasebe T, Tsuda H, Tsubono Y, Imoto S, Mukai K. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn J. Cancer Res. 1997 88 590 599.
6. Jitsuiki Y, Hasebe T, Tsuda H et al. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast. Mod. Pathol. 1999 12 492 498.
7. Hasebe T, Imoto S, Ogura T, Mukai K. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast. Jpn J. Cancer Res. 1997 88 877 885.
8. Sato N, Maehara N, Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res. 2004 64 6950 6956.
9. Dasu MR, Hawkins HK, Barrow RE, Xue H, Herndon DN. Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. J. Pathol. 2004 202 476 485.
10. Gallagher PG, Bao Y, Prorock A et al. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res. 2005 65 4134 4146.
11. Piccinini G, Luchetti MM, Caniglia ML et al. c-myb proto-oncogene is expressed by quiescent scleroderma fibroblasts and, unlike B-myb gene, does not correlate with proliferation. J. Invest. Dermatol. 1996 106 1281 1286.
12. Phan TT, Lim IJ, Aalami O et al. Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. J. Pathol. 2005 207 232 242.
13. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002 196 254 265.
14. Colpaert C, Vermeulen P, Jeuris W et al. Early distant relapse in 'node-negative' breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J. Pathol. 2001 193 442 449.
15. Colpaert C, Vermeulen P, van Beest P et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001 39 416 425.
16. Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res. Treat. 2003 81 137 147.
17. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol. 2000 24 197 202.
18. Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum. Pathol. 1999 30 1134 1139.
19. Baak JP, Colpaert CG, van Diest PJ et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur. J. Cancer 2005 41 2093 2101.
20. Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, Ochiai A. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod. Pathol. 2002 15 502 516.
21. Nakatsura T, Hasebe T, Tsubono Y et al. Histological prognostic parameters for adenocarcinoma of the pancreatic head: proposal for a scoring system for prediction of outcome. J. Hep. Bil. Pancr. Surg. 1997 4 441 448.
22. Watanabe I Hasebe T Sasaki S et al. Advanced pancreatic ductal cancer: fibrotic focus and beta-catenin expression correlate with outcome. Pancreas 2003 26 326 333.
23. Couvelard A, O'Toole D, Leek R et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005 46 668 676.
24. Nishimura R, Hasebe T, Tsubono Y et al. The fibrotic focus in advanced colorectal carcinoma: a hitherto unrecognized histological predictor for liver metastasis. Virchows Arch. 1998 433 517 522.
25. Suzuki K, Yokose T, Yoshida J et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann. Thorac. Surg. 2000 69 893 897.
26. Sakurai H, Maeshima A, Watanabe S et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am. J. Surg. Pathol. 2004 28 198 206.
27. Terasaki H, Niki T, Matsuno Y et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am. J. Surg. Pathol. 2003 27 937 951.
28. Maeshima AM, Niki T, Maeshima A, Yamada T, Kondo H, Matsuno Y. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer 2002 95 2546 2554.
29. Takise A, Kodama T, Shimosato Y, Watanabe S, Suemasu K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988 61 2083 2088.
30. Shimosato Y, Suzuki A, Hashimoto T et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am. J. Surg. Pathol. 1980 4 365 373.
31. Chalkley HW. Method for the quantitative morphologic analysis of tissues. J. Natl Cancer Inst. 1943 4 47 53.
32. Van den Eynden GG, Van der Auwera I, Van Laere SJ et al. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br. J. Cancer 2005 93 1128 1136.
33. Colpaert CG, Vermeulen PB, Van Beest P et al. Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology 2003 42 530 540.
34. Couvelard A, O'Toole D, Turley H et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 2005 92 94 101.
35. Van der Auwera I, Van den Eynden GG, Colpaert CG et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin. Cancer Res. 2005 11 7637 7642.
36. Van den Eynden GG, Van der Auwera I, Van Laere SJ et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br. J. Cancer 2006 94 1643 1649.
37. Chia SK, Wykoff CC, Watson PH et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 2001 19 3660 3668.
38. Schindl M, Schoppmann SF, Samonigg H et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 2002 8 1831 1837.
39. Bos R, van der Groep P, Greijer AE et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003 97 1573 1581.
40. Dery MA, Michaud MD. Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell Biol. 2005 37 535 540.
41. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006 6 392 401.
42. Van der Auwera I, Cao Y, Tille JC et al. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br. J. Cancer 2006 95 1611 1625.
43. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005 46 31 36.
44. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann. Surg. Oncol. 1998 5 271 278.
45. Kuwabara K, Ogawa S, Matsumoto M et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl Acad. Sci. USA 1995 92 4606 4610.
46. Falanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB. Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts. J. Invest. Dermatol. 1991 97 634 637.
47. Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res. 1994 54 6083 6086.
48. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002 2 38 47.
49. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004 9 (Suppl. 5 10 17.
50. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999 59 5002 5011.
51. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006 66 632 637.
52. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006 19 264 271.
53. Fulford LG, Easton DF, Reis-Filho J, S et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006 49 22 34.
54. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 415 530 536.
55. Tanigawa N, Matsumura M, Amaya H et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997 79 220 225.
56. Saito H, Tsujitani S. Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. Anticancer Res. 2001 21 4365 4372.
57. Di Leo S, Caschetto S, Garozzo G et al. Angiogenesis as a prognostic factor in cervical carcinoma. Eur. J. Gynaecol. Oncol. 1998 19 158 162.
58. Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res. 2001 21 4383 4388.
59. Giatromanolaki A. Prognostic role of angiogenesis in non-small cell lung cancer. Anticancer Res. 2001 21 4373 4382.
60. Streeter EH, Harris AL. Angiogenesis in bladder cancer - prognostic marker and target for future therapy. Surg. Oncol. 2002 11 85 100.
61. Des Guetz G, Uzzan B, Nicolas P et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer 2006 94 1823 1832.
62. Ikeda N, Adachi M, Taki T et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer 1999 79 1553 1563.